drugset / Trial / NCT02229825

Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression

NCT02229825

Phase 4 Completed 339 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess efficacy of Duloxetine 120 mg and Duloxetine 60 mg in patients hospitalized for severe depression after 4 weeks of treatment. To evaluate the rescue option in non-responding patients. Safety of Duloxetine will also be assessed.

Timeline

Start
2007-02-09
Primary completion
2008-08-26
Completion
2008-08-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg
Subject Duloxetine Small molecule 120 mg